On April 16, the US FDA granted Orphan Drug Designation to eftilagimod alfa for the treatment of Soft Tissue Sarcoma (STS). This drug targets a rare cancer with significant unmet medical needs.
Cellectar Biosciences has officially enrolled the first patient in its Phase 1b clinical trial evaluating CLR 125 for the treatment of refractory triple-negative breast cancer (TNBC). The investigational drug utilizes innovative Auger-emitting radioconjugate technology designed to target aggressive cancer cells. This…
Read the full storyThe U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Climb Bio’s drug candidate, budoprutug, for the treatment of primary membranous nephropathy (pMN). Budoprutug is an anti-CD19 monoclonal antibody targeting this rare kidney disease, for which there are currently no FDA-approved…
Immutep Limited announced that the US FDA has granted Orphan Drug Designation to its lead product candidate, eftilagimod alfa, for the treatment of Soft Tissue Sarcoma (STS). This designation targets a rare form of cancer where significant unmet medical needs persist. The Orphan Drug status provides Immutep with…